In the future, such decisions should be taken within 120 days for innovative medicines, as a rule, and for generic medicinal products within only 30, instead of 180 days today.
Edaspidi tuleks sellised otsused teha innovatiivsete ravimite puhul reeglina 120 päevaga ja geneeriliste ravimite puhul vaid 30 päevaga praeguse 180 päeva asemel.